NCT07052032 - An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

CND261

CND261 will be dosed according to the assigned cohort

Trial Locations (4)

RECRUITING

Candid Clinical Site, Tbilisi

RECRUITING

Candid Clinical Site, Chisinau

RECRUITING

Candid Clinical Site, Auckland

RECRUITING

Candid Clinical Site, Kyiv, Kyiv